复星医药(02196)：复迈宁®新增适应症上市申请获受理并获纳入优先审评程序

Core Viewpoint - Fosun Pharma's subsidiary has received acceptance for a new drug application for a treatment targeting adult patients with symptomatic, unresectable plexiform neurofibromas associated with Neurofibromatosis type 1, which is now under priority review by the National Medical Products Administration [1] Group 1 - Fosun Pharma's subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., has independently developed the drug Ruimai Ning® (generic name: Luwomeitini tablets) [1] - The new indication for the drug is aimed at treating adult patients with Neurofibromatosis type 1 (NF1) who have symptomatic and unresectable plexiform neurofibromas [1] - The drug application has been accepted by the National Medical Products Administration and included in the priority review process [1]